This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Praxair Inc. (PX) Tops Q1 Earnings and Revenues, View Solid
by Zacks Equity Research
Praxair Inc. (PX) reported impressive results for first-quarter 2018, with earnings and revenues surpassing their respective Zacks Consensus Estimate by 5.8% and 2.4%.
Should You Invest in the Fidelity MSCI Materials Index ETF (FMAT)?
by Zacks Equity Research
Sector ETF report for FMAT
Chemical Stock Earnings Slated on Apr 26: APD, EMN & More
by Zacks Equity Research
Earnings momentum for the chemical industry is expected to continue in Q1 as the fundamental driving factors remain in place.
Praxair (PX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Praxair's (PX) first-quarter 2018 earnings are to gain from solid U.S. industrial activities as well as strong demand in China. Seasonal weakness and lower Gulf Coast activities are to be a drag.
Praxair's Yara Freeport Contract to Boost Hydrogen Business
by Zacks Equity Research
Praxair's (PX) long-term supply agreement with Yara Freeport LLC is to solidify its businesses, especially of the hydrogen unit, in Texas.
Here's Why You Should Add Praxair (PX) to Your Portfolio
by Zacks Equity Research
Praxair (PX) stands to gain from a solid product portfolio and increasing applications of industrial gases. Returning value to shareholders is a priority.
Watch These ETFs as Trade War Risks Rise
by Zacks Equity Research
Donald Trump announced plans to impose tariffs on Steel and Aluminum imports.
Why Is Praxair (PX) Down 4.7% Since its Last Earnings Report?
by Zacks Equity Research
Praxair (PX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Lies Ahead for Materials ETFs?
by Zacks Equity Research
China threatens to retaliate if the United States moves ahead with tariffs on metal imports.
Monsanto Battles Market Rivalry on Innovation & Bayer's Deal
by Zacks Equity Research
Monsanto Company's (MON) performance to be driven by stronger innovation and Bayer AG's pending buyout deal. However, stiff business rivalry and rising debt remain causes of concern.
Top Analyst Reports for Johnson & Johnson, Illinois Tool Works & BNY Mellon
by Mark Vickery
Today's Research Daily features new research reports on 14 major stocks, including Johnson & Johnson (JNJ), Illinois Tool Works (ITW) and Bank of New York Mellon (BK).
Praxair (PX) Tops Q4 Earnings, Linde Merger to Close in 2H18
by Zacks Equity Research
Praxair's (PX) fourth-quarter 2017 adjusted earnings benefit from solid segmental performance, partially offset by rise in costs and expenses.
Praxair Inc. (PX) Beats Q4 Earnings and Revenues
by Zacks Equity Research
Praxair Inc's (PX) fourth-quarter 2017 earnings surpassed the Zacks Consensus Estimate by 2.7% while revenues surpassed by 3.6%.
Praxair (PX) Secures Gas Supply Contract From EverDisplay
by Zacks Equity Research
Praxair, Inc. (PX) fortifies business in China on the back of recently-secured long-term gas supply deal from EverDisplayOptronics.
Should You Buy Praxair (PX) Ahead of Earnings?
by Zacks Equity Research
Praxair (PX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Will Demand & Contract Wins Aid Praxair's (PX) Q4 Earnings?
by Zacks Equity Research
Praxair's (PX) Q4 earnings are likely to gain from strengthening end-market demand and growing applications for industrial gases.
Praxair (PX) Extends Hydrogen Supply Contract With Motiva
by Zacks Equity Research
Increasing application of industrial gases in manufacturing, transportation, healthcare, food and beverages, and metal fabrication industries is beneficial for Praxair (PX).
Top Stock Reports for PepsiCo, Walgreens Boots & EOG Resources
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Walgreens Boots (WBA) and EOG Resources (EOG).
Can Sucampo Acquisition Turn Mallinckrodt Stock Around?
by Zacks Equity Research
Mallinckrodt (MNK) faced challenging business conditions in 2017 and the company is now looking to revive business with the recently announced Sucampo acquisition.
Mallinckrodt to Buy Sucampo for $1.2B to Diversify Portfolio
by Zacks Equity Research
Mallinckrodt (MNK) is all set to acquire Sucampo Pharmaceuticals to diversify its portfolio and counter the decline in sales of its largest drug, Acthar.
Here's Why You Should Hold on to Praxair (PX) Stock Now
by Zacks Equity Research
Praxair (PX) is well-poised to gain traction from solid contract wins, capital allocation policy and diversified business structure. Industry competition and rising costs remain issues.
Praxair Hikes Gas Prices to Cover High Energy & Labor Costs
by Zacks Equity Research
Praxair (PX) is poised to gain from increasing applications of industrial gases. Up to 15% hike in gas prices will help it recover increasing costs.
Why Is Praxair (PX) Up 4.5% Since the Last Earnings Report?
by Zacks Equity Research
Praxair (PX) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mallinckrodt (MNK) Down 55% Year to Date: What Lies Ahead?
by Zacks Equity Research
Mallinckrodt plc (MNK)'s stock lost 55% in the year so far due to ongoing investigations and weakness in Acthar and Inomax.
Materials ETFs Head to Head: XLB vs. IYM
by Zacks Equity Research
Head to Head comparison of two financials ETFs, XLB and IYM.